M acrophage responses to modified low-density lipoproteins (modLDLs; eg, oxidized LDL [oxLDL]) contribute to atherosclerosis progression. Internalization of modLDL by macrophages results in the generation of a lipidladen phenotype (foam cell) and generation of proinflammatory mediators. The foam cell phenotype results from both enhanced modLDL uptake via scavenger receptor recognition and reduced ability to process cholesterol and deliver it to high-density lipoproteins. 1 Uptake of modLDLs is also known to induce production of proinflammatory cytokines, such as TNF-α (tumor necrosis factor-α), interleukin-6, interleukin-1, prostaglandin E2, C-C motif chemokine ligand 2, etc, that promote atherosclerosis. 2 However, the mechanism through which foam cells become proinflammatory has been elusive. ModLDLs can be recognized by macrophages in vitro as pathogens via pattern recognition receptors, such as TLR2 (toll-like receptor 2), TLR4, and NLRP3 (NLR family pyrin domain containing 3), resulting in acute signaling responses that elicit proinflammatory mediator production.
formation but can also mediate macrophage proinflammatory responses. [9] [10] [11] Together, these data suggest that glycerolipid synthesis may provide an additional mechanism by which modLDLs influence macrophage proinflammatory responses.
ModLDLs are engulfed by macrophages and broken down by lysosomal acid lipases within endosomes, resulting in the generation of free cholesterol and free fatty acids. 12 Excess free cholesterol is esterified at the endoplasmic reticulum and then stored in lipid droplets, which give foam cells their phenotypic appearance. 1 Although the composition of foam cell lipid droplets is dominated by cholesterol esters, they also contain triacylglycerol and phosphatidylcholine. 12, 13 One lipid synthetic pathway that contributes to lipid droplet generation in macrophages is the glycerolipid synthetic pathway, which produces triacylglycerol and phosphatidylcholine. 14 Glycerolipid synthesis consists of 4 enzymatic steps in which glycerol-3-phosphate is converted into triacylglycerol or phosphatidylcholine at the endoplasmic reticulum. Sequential esterification of glycerol-3-phosphate with acyl-CoA-charged long-chain-fatty-acids by glycerol phosphate acyltransferase and lysophosphate-acyl transferase enzymes produces phosphatidic acid. Phosphatidic acid is dephosphorylated by the phosphatidic acid phosphatase, lipin-1, to generate diacylglycerol. Diacylglycerol can then be converted into triacylglycerol by diglyceride acyltransferase enzymes or phosphatidylcholine via the activity of diacylglycerol:cholinephosphotransferase. 15 The inhibition of long-chain-fatty-acid-CoA ligase (with triacin C), the genetic deletion of diglyceride acyltransferase 1, or genetic reduction of lipin-1 all result in reduced foam cell formation in response to modLDLs. 10, 11, 16 Thus, these studies provide evidence that glycerolipid synthesis contributes to foam cell formation.
Glycerolipid synthesis has been shown to influence immune cell function and enhance inflammation. [17] [18] [19] Our laboratory and others have demonstrated that lipin-1, a key regulatory enzyme in the glycerolipid synthetic pathway, mediates diacylglycerol production and contributes to proinflammatory responses in lipopolysaccharide (LPS)-, oxLDL-, and acetylated LDL-stimulated macrophages. 9, 10 Lipin-1 is a bifunctional enzyme with both enzymatic phosphatidic acid phosphatase activity and transcriptional coregulatory activity. 14, 20 However, only lipin-1 enzymatic activity is required for glycerolipid synthesis. 21 The contribution of lipin-1 to macrophage proinflammatory responses led us to hypothesize that macrophage-associated lipin-1 enzymatic activity influences atherosclerosis development. To evaluate the role of macrophage-associated lipin-1 enzymatic activity in atherosclerosis, we developed a mouse model with a myeloid-specific deletion of lipin-1 enzymatic activity (lipin-1 mEnzy KO) and induced atherosclerosis using the adeno-associated viral vector 8 expressing a gain-of-function mutation (D377Y) of mouse proprotein convertase subtilsin/kexin type 9 (referred to as adeno-associated viral vector 8-proprotein convertase subtilisin/kexin type 9) and high-fat diet. 22 In addition, our in vitro studies provide evidence as to the molecular mechanisms by which macrophage-associated lipin-1 enzymatic activity promotes atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Myeloid-Associated Lipin-1 Is Atherogenic
To investigate the potential contribution of macrophage-associated lipin-1 on atherosclerosis, we generated mice lacking lipin-1 enzymatic activity in myeloid-derived cells. Lpin1-floxed (lipin-1 flox/flox ) mice were crossed with LysM-Cre mice to generate myeloid-specific lipin-1 enzymatic knockout (lipin-1 mEnzy KO) mice. Because of the location of the flox sites in these lipin-1 flox/flox mice, the original translational start site is lost, but an alternative start site is enforced and the resulting truncated lipin-1 protein lacks enzymatic activity while transcriptional coregulatory function is retained. 23 Equal amounts of lipin-1 were present in nonmyeloidderived tissue from the heart and lung in lipin-1 mEnzy KO and lipin-1 flox/flox littermate control mice ( Figure 1A ). Bone marrow-derived macrophages (BMDMs) derived from lipin-1 mEnzy KO mice have a smaller lipin-1 band compared with the lipin-1 band detected in the lipin-1 flox/flox BMDMs, and the smaller band represents the truncated form of lipin-1 23 ( Figure 1A ). We first wanted to verify that BMDMs from lipin-1 mEnzy KO mice responded to oxLDL in a manner similar to the lipin-1-depleted RAW264.7 macrophage cell line. 10 RAW264.7 macrophages lacking lipin-1 have reduced foam cell formation and diacylglycerol production while cholesterol uptake and scavenger receptor expression remain unaltered in response to oxLDL as compared with control RAW264.7 macrophages. 10 Consistent with this, liquid chromatography tandem mass spectrometry analysis showed that lipin-1 mEnzy KO BMDMs had reduced diacylglycerol production 24 and 48 hours after oxLDL stimulation as compared with lipin-1 flox/flox control BMDMs ( Figure 1B) . Furthermore, analysis of cholesterol esters showed no difference in cholesterol content between the lipin-1 mEnzy KO and lipin-1 flox/flox control BMDMs ( Figure 1C ). Nile red analysis also demonstrated a reduction in lipid content of lipin-1 mEnzy KO BMDMs compared with lipin-1 flox/flox control BMDMs ( Figure 1D (Table) . We also determined atherosclerotic burden in lipin-1 flox/flox and lipin-1 mEnzy KO mice. Oil Red O staining of en face aortas revealed less plaque development in the aortas of lipin-1 mEnzy KO mice compared with the corresponding lipin-1 flox/flox controls ( Figure 1E ). In addition, Movat staining and subsequent analysis of the aortic root demonstrated reduced plaque area in lipin-1 mEnzy KO mice compared with the corresponding lipin-1 flox/flox mice ( Figure 1F ). Immunofluorescent analysis of the aortic root showed no significant difference in plaque composition ( Figure IIE and IIF in the online-only Data Supplement), suggesting that monocyte recruitment is similar between lipin-1 mEnzy KO and lipin-1 flox/flox mice. Our data suggest that lipin-1 enzymatic activity is responsible for the decreased severity of atherosclerosis seen in the lipin-1 mEnzy KO mice. However, because truncated proteins are known to undergo enhanced degradation in vivo, it is possible that the loss of lipin-1 transcriptional coregulatory activity contributes to changes in atherosclerosis severity in our mouse model. However, this is unlikely as this lipin-1 flox/flox mouse has been used in other studies to investigate lipin-1 transcriptional coregulatory activity in hepatocytes. 24 Furthermore, lipin-1 has been demonstrated to enhance the activity of transcription factors, such as peroxisome proliferator-activated receptor γ, peroxisome proliferator-activated receptor α, and peroxisome proliferator-activated receptor γ coactivator-1α, which are known to induce an atheroprotective response. [25] [26] [27] [28] [29] The known interactions of lipin-1 transcriptional coregulatory activity suggest that the degradation of the truncated lipin-1 protein in our mice would enhance atherosclerosis severity, which is in contrast to our data. We also evaluated peroxisome proliferator-activated receptor γ-regulated gene expression by quantitative reverse transcription polymerase chain reaction to determine whether lipin-1 transcriptional coregulatory activity was altered in our lipin-1 mEnzy KO BMDMs and observed no differences between lipin-1 mEnzy KO and lipin-1 flox/flox BMDMs after oxLDL stimulation ( Figure IB in the online-only Data Supplement). These data suggest that lipin-1 transcriptional coregulatory activity is either not active or is unaltered in lipin-1 mEnzy KO BMDMs in response to oxLDL.
These data demonstrate that lipin-1 mEnzy KO mice have less severe atherosclerosis even when plasma cholesterol levels are similar to control mice, suggesting that myeloid-associated lipin-1 enzymatic activity positively contributes to the development of atherosclerosis in vivo.
ModLDL Stimulation of BMDMs Results in Activation of a PKCα/βII-ERK1/2-cJun Signaling Cascade
Having demonstrated that myeloid-associated lipin-1 enzymatic activity is proatherogenic in vivo (Figure 1 ), we sought to determine the molecular mechanism by which macrophageassociated lipin-1 enzymatic activity may contribute to atherosclerosis. Lipin-1 mediates oxLDL-and LPS-induced diacylglycerol production and LPS-induced MAPK (mitogenactivated protein kinase) and AP-1 (activator protein-1) activity in macrophages. 30 Furthermore, the engulfment, breakdown, and storage of cholesterol and lipids from modLDLs is an ongoing process in the macrophage as long as modLDLs are present. These observations led us to hypothesize that lipin-1 enzymatic activity is responsible for persistent activation of a PKC-MAPK-AP-1 signal transduction pathway in macrophages in response to modLDL stimulation. We first set out to determine whether there is persistent activation of a PKC-MAPK-AP-1 signal transduction pathway in oxLDL-stimulated macrophages. The phosphorylation status of PKCs, MAPKs, and the AP-1 subunits were monitored via Western blot analysis as a correlate of protein activity at 4, 24, and 48 hours after oxLDL stimulation. Phosphorylations of PKCα/βII, PKCδ, PKCθ, and PKCμ were evaluated in wild-type (WT) BMDMs stimulated with oxLDL. We failed to detect total or phosphorylated PKCθ and PKCμ in WT BMDMs. Although phosphorylation of PKCδ was detected, the level of phosphorylation remained unchanged during the 48-hour period (Figure 2A ). PKCα/βII phosphorylation was elevated at 4, 24, and 48 hours after oxLDL stimulation (Figure 2A and 2B) . Analysis of MAPK phosphorylation demonstrated increased phosphorylation of ERK1/2 at 4, 24, and 48 hours after oxLDL stimulation ( Figure 2C and 2D ). Sustained phosphorylation of JNK1/2 and protein 38 was not observed at these time points ( Figure 2C ). Finally, phosphorylation of the AP-1 subunits, jun protooncogene (cJun) and fos proto-oncogene, was evaluated. The phosphorylation of both cJun and fos proto-oncogene was elevated after 4 hours of oxLDL stimulation ( Figure 2E ). However, only cJun remained phosphorylated at 24 and 48 hours after treatment, whereas fos proto-oncogene returned to basal levels ( Figure 2E and 2F). The phosphorylation of cJun initiates its translocation to the nucleus where it can either bind to fos proto-oncogene or homodimerize to form AP-1. 31, 32 To determine whether cJun was localizing to the nucleus of oxLDL-stimulated BMDMs, we performed immunocytochemistry and observed nuclear cJun in WT BMDMs at 4, 24, and 48 hours after oxLDL stimulation ( Figure 2G and 2H). To determine whether these 3 proteins were linked in a signaling cascade, we used the small molecule inhibitors Gӧ6376 (PKCα/βII) and U0126 (inhibits MEK1/2 [mitogen-activated protein kinase kinase1/2] directly upstream of ERK1/2) to determine whether PKCα/βII and ERK1/2 were upstream of cJun. Because of the fact that PKCs and MAPKs directly contribute to oxLDL internalization by macrophages, inhibitors were added 24 hours after oxLDL treatment as to not confound the data interpretation. 33 Both small molecules inhibited the phosphorylation of cJun ( Figure IIIA and IIIB in the online-only Data Supplement), suggesting that we identified a linked PKCα/βII-ERK1/2-cJun signaling pathway. To ensure the signaling responses observed in oxLDL-stimulated macrophages were not because of LPS contamination, WT macrophages were stimulated with 1.2 pg/mL LPS (maximum calculated endotoxin present in the modLDL preparations), 60 pg/mL (50× the maximum endotoxin present in the modLDL preparations), or 10 ng/mL of LPS (amount of LPS used in Figure 5 ). Persistent phosphorylation of the PKCα/βII-ERK1/2-cJun pathway was not observed in any of the LPS treatments ( Figure IV in the online-only Data Supplement).
To ensure that persistent activation of the PKCα/βII-ERK1/2-cJun pathway was not because of a single type of LDL modification, WT macrophages were stimulated with 25 µg/mL acetylated LDL or 25 µg/mL oxLDL. Stimulation with either oxLDL or acetylated LDL resulted in sustained phosphorylation of PKCα/βII, ERK1/2, and cJun at 24 and 48 hours ( Figure 3A and 3B). Together these results suggest that modLDL stimulation of macrophages induces persistent activation of a PKCα/βII-ERK1/2-cJun signaling axis.
OxLDL Stimulation of BMDMs Activates the Lipin-1-Dependent Signaling Cascade PKCα/βII-ERK1/2-cJun
To determine whether the PKCα/βII-ERK1/2-cJun pathway is lipin-1 dependent, the phosphorylation status of PKCα/βII, ERK1/2, and cJun was evaluated in BMDMs generated from lipin-1 mEnzy KO and lipin-1 flox/flox mice. BMDMs were stimulated with 25 µg/mL oxLDL, and protein was collected at 4, 24, and 48 hours for Western blot analysis. Lipin-1 mEnzy KO BMDMs had reduced phosphorylation of PKCα/βII, ERK1/2, and cJun at the 24-and 48-hour time points compared with the lipin-1 flox/flox BMDMs ( Figure 4A and 4B), suggesting that the persistent phosphorylation events of these proteins are dependent on lipin-1 enzymatic activity. These data demonstrate that PKCα/βII-ERK1/2-cJun is a lipin-1-dependent signaling cascade activated in response to oxLDL stimulation.
Lipin-1 Contributes to oxLDL-Elicited TNF-α Production in BMDMs
We previously demonstrated that oxLDL elicits TNF-α production by RAW264.7 macrophages in a lipin-1-dependent manner. 10 To determine whether lipin-1 enzymatic activity regulates TNF-α production in BMDMs in response to oxLDL, lipin-1 mEnzy KO and lipin-1 flox/flox BMDMs were stimulated with 25 µg/mL of oxLDL, and TNF-α production in supernatants was analyzed by enzyme-linked immunosorbent assay 48 hours after stimulation. This late time point Figure 3 . Acetylated low-density lipoprotein (AcLDL) stimulation of bone marrow-derived macrophages (BMDMs) also induces prolonged phosphorylation of PKC (protein kinase C) α/βII, ERK (extracellular receptor kinase) 1/2, and cJun (jun proto-oncogene). BMDMs from wild-type mice were left untreated or stimulated with 25 μg/mL oxidized low-density lipoprotein (oxLDL) or acLDL. At 0, 4, 24, and 48 h after stimulation, total cellular protein was collected for Western blot analysis. Image J was used to determine changes in protein amounts in Western blot images (mean±SEM; n=7-8; *P≤0.05). A, Representative Western blot images of phosphorylation of PKCα/βII, ERK1/2, and cJun. B, Graphical representation of fold change analysis of phosphorylated PKCα/βII, ERK1/2, and cJun over untreated (0 h) samples. (48 hours) was chosen as it corresponds to the time of maximal TNF-α production by oxLDL-stimulated RAW264.7 macrophages. 10 However, stimulation of BMDMs with oxLDL alone failed to elicit TNF-α from either the lipin-1 mEnzy KO or lipin-1 flox/flox BMDMs ( Figure 5A ). Based on previous findings in RAW264.7 macrophages, we reasoned that the lack of TNF-α production by BMDMs might be a result of low basal nuclear factor (NF)-κB activity. 10 In contrast to untreated RAW264.7 macrophages, there was no NF-κB (p65) phosphorylation in untreated WT BMDMs as detected by Western blot analysis ( Figure 5D ). In addition, immunocytochemistry confirmed that NF-κB (p65) was not present in the nucleus of untreated or oxLDL-stimulated WT BMDMs ( Figure 5E ).
The presence of pre-existing NF-κB activity in the RAW264.7 macrophage cell line is noteworthy because oxLDL alone does not induce NF-κB activity in BMDMs, which is required for TNF-α production. 34 In addition, AP-1 transcriptional activity is not sufficient for TNF-α production but can enhance the activity of other transcription factors in macrophages, including NF-κB, to augment TNF-α production. 35 Thus, we hypothesized that lipin-1-mediated activation of cJun (AP-1) triggered by oxLDL treatment may prime macrophages to be more responsive to a subsequent NF-κB activating stimulus, such as LPS. To examine the effect of an NF-κB stimulus on oxLDL-stimulated macrophages, we treated WT (lipin-1 flox/flox ) BMDMs with either (1) 25 µg/mL oxLDL, (2) 10 ng/mL LPS, or (3) 25 µg/mL oxLDL for 24 hours and then 10 ng/mL LPS for an additional 24 hours. Supernatants were collected 48 hours after oxLDL addition and evaluated by enzyme-linked immunosorbent assay for TNF-α production. LPS stimulation resulted in TNF-α production in WT BMDMs and stimulation of WT BMDMs with oxLDL and LPS resulted in augmented TNF-α production ( Figure 5A ).
We next wanted to determine whether the identified lipin-1-dependent PKCα/βII-ERK1/2-cJun signaling axis was responsible for augmented TNF-α production in BMDMs stimulated with both oxLDL and LPS. Lipin-1 mEnzy KO and lipin-1 flox/flox BMDMs were treated with either (1) 25 µg/mL oxLDL, (2) 10 ng/mL LPS, or (3) 25 µg/mL oxLDL for 24 hours followed by addition of 10 ng/mL LPS for an additional 24 hours. LPS alone induced TNF-α production in both the lipin-1 mEnzy KO and lipin-1 flox/flox BMDMs ( Figure 5A ). However, preloading lipin-1 flox/flox BMDMs with oxLDL augmented LPS-elicited TNF-α production, which was not observed in the lipin-1 mEnzy KO BMDMs ( Figure 5A ). Next, WT BMDMs were stimulated with either (1) oxLDL, (2) LPS, or (3) oxLDL and LPS with inhibitors of PKCα/βII (Gӧ6376) and ERK1/2 (U0126). Inhibitors were added at 24 hours along with LPS stimulation. Inhibition of PKCα/βII and ERK1/2 ablated oxLDL-augmented LPSinduced TNF-α production ( Figure 5B) . Finally, to determine whether the augmented TNF-α production by lipin-1 flox/flox BMDMs stimulated with oxLDL and LPS was because of elevated cJun activity, cJun was depleted using small interfering RNA, and TNF-α production was examined after treatment. WT BMDMs were transfected with either nontarget small interfering RNA or cJun-targeted small interfering RNA ( Figure 5C ) and left untreated or stimulated with 25 µg/mL oxLDL for 24 hours before 10 ng/mL LPS treatment for an additional 24 hours. Depletion of cJun prevented the augmentation of LPS-elicited TNF-α production, similar to what was seen in the lipin-1 mEnzy KO BMDMs in Figure 5A ( Figure 5C ).
Inhibition of the macrophages ability to produce TNF-α in vivo results in reduced serum TNF-α levels in atherosclerotic mice. 36 Therefore, we wanted to determine whether there was a reduction in serum TNF-α in the lipin- Figure 5F ). Although these data are not definitive, this begins to provide evidence that lipin-1 enzymatic activity is contributing to the proinflammatory responses in vivo that promote atherosclerosis. These data suggest that oxLDL induces activation of cJun (AP-1) via lipin-1 enzymatic activity, which effectively primes the macrophage for enhanced responses to a proinflammatory stimulus above what would be exhibited by the proinflammatory stimulus alone.
Discussion
Using the lipin-1 mEnzy KO mouse model with the viral model of atherosclerosis, we demonstrated the loss of myeloidassociated lipin-1 enzymatic activity results in reduced atherosclerosis in mice fed high-fat diet for 8 and 12 weeks. Furthermore, we demonstrated that macrophage-associated lipin-1 enzymatic activity contributes to foam cell formation and regulates a diacylglycerol-dependent signaling cascade that results in persistent AP-1 activation in response to modLDL. Persistent activation of AP-1 primes the macrophage to be hyper-responsive to LPS-induced TNF-α production. Although the glycerolipid synthetic pathway is likely not the only lipid synthesis pathway contributing to foam cell formation, it is a critical pathway that influences modLDL-elicited proinflammatory responses. Taken together, our data highlight the dynamic interaction between modLDL-elicited lipid synthetic events and their contribution to macrophage proinflammatory mediator production that promotes atherosclerosis.
The combination of our in vitro and in vivo data suggest that the reduced plaque development observed in the lipin-1 mEnzy KO mice is due primarily to monocytes and macrophages. However, LysM-Cre was used to knockout lipin-1 enzymatic activity in these mice, and LysM expression is not restricted to monocytes and macrophages. Analysis of LysM-Cre-mediated gene deletion demonstrates gene excision in dendritic cells and granulocytes, as well as monocytes and macrophages. 37, 38 The contribution of dendritic cells to atherosclerosis is unclear because tools to specifically deplete this population long term are currently lacking. However, the few studies using CD11cDTR mice, in which dendritic cells are transiently depleted, demonstrate no alteration in plaque size or composition. 39 The contribution of lipin-1 to dendritic cell function is completely unknown and will need to be looked at in the future. Neutrophils clearly contribute to atherosclerosis progression because they can be identified in both early and advanced murine and human plaques, and antibody depletion of neutrophils has been shown to contribute to plaque burden in mice. [40] [41] [42] However, lipin-1 is not readily detected in neutrophils, suggesting that lipin-1 has little contribution to neutrophil function. 9 Thus, we propose that the loss of lipin-1 enzymatic activity in monocytes and macrophages is most likely responsible for the reduction in atherosclerosis observed in the lipin-1 mEnzy KO mice. Our studies identified a novel mechanism through which lipin-1, a regulatory enzyme in the glycerolipid synthesis pathway, initiates a diacylglycerol-mediated PKCα/βII-ERK1/2-cJun signaling cascade that contributes to macrophage proinflammatory responses to modLDL. Glycerolipid synthesis is a universal pathway required for the storage of incoming lipids. We demonstrate that stimulation of macrophages with both oxLDL and acetylated LDL results in sustained phosphorylation of the PKCα/βII-ERK1/2-cJun pathway up to 48 hours. The initiation of glycerolipid synthesis by any modLDL would then be capable of activating the diacylglycerol-dependent PKCα/βII-ERK1/2-cJun signaling pathway leading to persistent macrophage proinflammatory responses. Acute macrophage proinflammatory responses have been investigated as a result of modLDLs being recognized by toll-like receptors or the inflammasome. [3] [4] [5] [6] However, our data highlight another molecular mechanism by which modLDLs can elicit signaling that contributes to macrophage proinflammatory responses that may be independent of receptor-mediated recognition of modLDLs. Our data investigating PKCα/βII support this proposed alternative mechanism because PKCβ is required for modLDL uptake in vitro. 43 However, the lipin-1 mEnzy KO macrophages do not have an oxLDL uptake deficiency even with a loss of PKCβ phosphorylation, suggesting that late activity of PKCα/βII (24 and 48 hours after oxLDL stimulation) is dependent on lipin-1 while early activation (up to 4 hours) is not. This supports the idea that there are multiple signals that contribute to modLDLinduced proinflammatory responses in a temporal manner. Our studies identified ERK1/2 and cJun as downstream proteins of PKCα/βII. Although JNK1/2 is the classical kinase associated with phosphorylation of cJun, ERK1/2 can also phosphorylate cJun specifically at Ser63 and Ser72. 44, 45 The ability of ERK1/2 to phosphorylate cJun may also be temporally regulated. Studies using total knockout of JNK1/2 in mice show prevention of the early steps of atherosclerosis and thus reduction in plaque burden. 46 However, inhibition of JNK1/2 during late stage atherosclerosis in humans showed minimal effects on levels of proinflammatory mediators in serum. 47 We hypothesize that targeting JNK1/2 in the human study was ineffective because ERK1/2 may be responsible for chronic activation of cJun in macrophages during later stages of atherosclerosis. Overall, our data support the idea that there is a temporal difference in signaling responses that is determined by macrophage interactions with modLDLs. Early signaling seems to be dependent on receptor interactions and later signaling events are dependent on prolonged lipid synthetic events.
The persistent activation of the PKCα/βII-ERK1/2-cJun signaling axis primes macrophages to be hyper-responsive to secondary proinflammatory stimuli, such as LPS. Many of the comorbidities that contribute to atherosclerosis progression are associated with increased endotoxin levels in the plasma, called endotoxemia. As expected, chronic bacterial infections, such as periodontitis and chlamydial infections, increase plasma endotoxin levels, and noninfectious comorbidities, such as obesity, consumption of a high-fat diet (both in mice and humans), type 2 diabetes mellitus, and alcoholism, also result in increased serum endotoxin levels. [48] [49] [50] [51] [52] [53] [54] Enhanced macrophage proinflammatory responses induced via cooperation of AP-1 and NF-κB have previously been demonstrated to enhance vascular inflammation when compared with NF-κB (via LPS stimulation) alone. 35 Our data provide a molecular mechanism by which hypercholesterolemia and endotoxemia promote proinflammatory responses that mediate atherosclerosis. We have provided evidence that oxLDL elicits persistent diacylglycerol generation that leads to AP-1 activation via a PKCα/βII-ERK1/2-cJun signaling axis in macrophages, and interruption of this pathway reduces enhanced proinflammatory responses (TNF-α; Figure 5 ). In vivo, the loss of lipin-1 from myeloidderived cells reduced circulating TNF-α levels in response to high-fat diet. Serum TNF-α levels often correspond to degree of plaque inflammation and growth. 55 This supports the hypothesis that macrophage-associated lipin-1 contributes to modLDL-elicited proinflammatory responses. Combining our in vitro observations of the contribution of lipin-1 to oxLDL-elicited proinflammatory responses with our in vivo data demonstrating that myeloid-associated lipin-1 contributes to atherosclerotic progression, suggests that lipid synthetic events required to store incoming lipids from modLDLs also mediate proinflammatory responses in macrophages that contribute to atheroma progression. We suggest hypercholesterolemia in vivo results in prolonged enhancement of glycerolipid synthesis within macrophages, priming the macrophage with active AP-1, resulting in macrophage foam cells that are hyper-responsive to additional proinflammatory stimuli (such as LPS).
A better understanding of the fundamental mechanisms of intrinsic plaque inflammation may provide additional therapeutic targets to reduce atherosclerosis better than statin therapy alone. Interestingly, the statins most effective at reducing cardiovascular disease risk are those that also exhibit anti-inflammatory properties. 56 We currently lack mechanisms to target plaque intrinsic inflammation without causing global immune suppression. Macrophage foam cell formation is largely unique to atherosclerosis, and our results suggest that modLDL-induced foam cell formation and modLDL-induced macrophage proinflammatory responses are linked via enhanced lipid synthesis. Thus, understanding of modLDL-elicited lipid synthetic events that contribute to macrophage proinflammatory responses may lead to an ideal therapeutic target to reduce plaque intrinsic inflammation without causing global immune suppression to reduce cardiovascular disease. 
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